Drug Trial Radar · NCT05738850
Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Jul 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
104
Actual
Start
Feb 15, 2023
Primary completion
May 31, 2024
Study completion May 31, 2024
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- Collaborators
- Gedeon Richter Plc.
- First posted
- Feb 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main objective of this study is to assess pharmacokinetics, safety, and tolerability of ABBV-932 in healthy adult participants.
Conditions
- Generalized Anxiety Disorder (GAD)
- Healthy Participants
Interventions
ABBV-932Drug
Oral Capsule
PlaceboDrug
Oral Capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Plasma Concentration (Cmax) of ABBV-932Time frame: Up to approximately 5 days
- Time to Cmax (Tmax) of ABBV-932Time frame: Up to approximately 5 days
- Terminal Phase Elimination Rate Constant (Beta) of ABBV-932Time frame: Up to approximately 5 days
- Terminal Phase Elimination Half-Life (t1/2) of ABBV-932Time frame: Up to approximately 5 days
- Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-932Time frame: Up to approximately 5 days
- Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-932Time frame: Up to approximately 5 days
- Maximum Plasma Concentration (Cmax) of DCARTime frame: Up to approximately 5 days
- Time to Cmax (Tmax) of DCARTime frame: Up to approximately 5 days
- Terminal Phase Elimination Rate Constant (Beta) of DCARTime frame: Up to approximately 5 days
- Terminal Phase Elimination Half-Life (t1/2) of DCARTime frame: Up to approximately 5 days
- Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of DCARTime frame: Up to approximately 5 days
- Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of DCARTime frame: Up to approximately 5 days
- Maximum Plasma Concentration (Cmax) of DDCARTime frame: Up to approximately 5 days
- Time to Cmax (Tmax) of DDCARTime frame: Up to approximately 5 days
- Terminal Phase Elimination Rate Constant (Beta) of DDCARTime frame: Up to approximately 5 days
- Terminal Phase Elimination Half-Life (t1/2) of DDCARTime frame: Up to approximately 5 days
- Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of DDCARTime frame: Up to approximately 5 days
- Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of DDCARTime frame: Up to approximately 5 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Anaheim Clinical Trials LLC /ID# 254178
Anaheim, California
Acpru /Id# 249639
Grayslake, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.